Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data
Portfolio Pulse from
Arcturus is progressing with its LUNAR-CF phase 2 study for Cystic Fibrosis, with interim results expected in the first half of 2025. The global Cystic Fibrosis market is projected to reach $62.57 billion by 2032. Additionally, interim results for LUNAR-OTC for OTC Deficiency are also expected in the first half of 2025.
November 14, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcturus is advancing its LUNAR-CF phase 2 study for Cystic Fibrosis, with interim results anticipated in the first half of 2025. The Cystic Fibrosis market is expected to grow significantly, potentially benefiting Arcturus if the study results are positive.
The news highlights the progress of Arcturus' LUNAR-CF study, which is crucial for its future market positioning in the growing Cystic Fibrosis market. Positive interim results could lead to increased investor confidence and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90